Verve Therapeutics, Inc.

NASDAQ:VERV

4.24 (USD) • At close May 28, 2025
Bedrijfsnaam Verve Therapeutics, Inc.
Symbool VERV
Munteenheid USD
Prijs 4.6
Beurswaarde 410,058,720
Dividendpercentage 0%
52-weken bereik 2.865 - 9.305
Industrie Biotechnology
Sector Healthcare
CEO Dr. Sekar Kathiresan M.D.
Website https://www.vervetx.com

An error occurred while fetching data.

Over Verve Therapeutics, Inc.

Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program

Vergelijkbare Aandelen

Merus N.V. logo

Merus N.V.

MRUS

55.37 USD

Avidity Biosciences, Inc. logo

Avidity Biosciences, Inc.

RNA

31.7 USD

Nektar Therapeutics logo

Nektar Therapeutics

NKTR

0.739 USD

Codexis, Inc. logo

Codexis, Inc.

CDXS

2.35 USD

HealthStream, Inc. logo

HealthStream, Inc.

HSTM

27.89 USD

Aurora Cannabis Inc. logo

Aurora Cannabis Inc.

ACB

5.52 USD

Evolus, Inc. logo

Evolus, Inc.

EOLS

9.34 USD

Rocket Pharmaceuticals, Inc. logo

Rocket Pharmaceuticals, Inc.

RCKT

2.62 USD

The Oncology Institute, Inc. logo

The Oncology Institute, Inc.

TOI

3.21 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)